#1 Clinical Trials Search in Europe

Trametinib

Trametinib is a promising drug being studied in various clinical trials for the treatment of different types of cancer. This article explores how trametinib is being used in clinical trials to potentially improve outcomes for patients with advanced or refractory cancers. We’ll look at its applications in solid tumors, leukemias, and specific cancer types like thyroid and lung cancer.

Table of Contents

What is Trametinib?

Trametinib is a medication used in cancer treatment. It is known by several names, including:

  • Mekinist (brand name)
  • GSK1120212
  • JTP-74057
  • MEK Inhibitor GSK1120212
Trametinib belongs to a class of drugs called MEK inhibitors. These drugs work by blocking certain proteins involved in cancer cell growth.[5]

How Trametinib Works

Trametinib targets and blocks proteins called MEK1 and MEK2. These proteins are part of a pathway in cells that controls growth and survival. In many types of cancer, this pathway is overactive, causing cancer cells to grow and spread uncontrollably. By inhibiting MEK1 and MEK2, trametinib can help stop or slow the growth of cancer cells.[4]

Specifically, trametinib blocks an enzyme pathway that cancer cells need to grow. When these proteins are blocked, cancer cell growth may be stopped, and the cancer cells may die.[5]

Conditions Treated with Trametinib

Trametinib is being studied and used to treat various types of cancer, including:

  • Advanced or metastatic solid tumors: This refers to cancers that have spread from their original location to other parts of the body.[1]
  • Thyroid cancer: Particularly radioiodine-refractory thyroid cancer, which doesn’t respond to standard radioactive iodine treatment.[2]
  • Cervical cancer: Specifically for recurrent or persistent cervical cancer.[3]
  • Oral cavity squamous cell cancer: A type of mouth cancer.[4]
  • Multiple myeloma: A cancer of plasma cells in the bone marrow.[6]
  • Non-small cell lung cancer (NSCLC): Particularly in patients with certain genetic mutations.[7]
  • Langerhans Cell Histiocytosis (LCH): A rare disorder that can affect various parts of the body.[8]

How Trametinib is Administered

Trametinib is typically taken orally (by mouth) once daily. The dosage may vary depending on the specific condition being treated and the patient’s individual factors. Some key points about trametinib administration include:

  • It is usually given in 28-day cycles.[6]
  • The typical adult dose is 2 mg once daily.[7]
  • For patients who cannot swallow pills, a liquid formulation may be available.[8]
  • Dose adjustments may be necessary based on how well the patient tolerates the medication.[7]

Ongoing Clinical Trials

Trametinib is being studied in various clinical trials to better understand its effectiveness and safety in different types of cancer. Some ongoing areas of research include:

  • Combining trametinib with other medications to enhance its effectiveness.[2]
  • Using trametinib in patients with liver dysfunction.[5]
  • Studying trametinib’s effects on specific genetic mutations in cancer cells.[7]
  • Evaluating trametinib as a treatment for rare disorders like Langerhans Cell Histiocytosis.[8]

Potential Side Effects

Like all medications, trametinib can cause side effects. Common side effects may include:

  • Skin rashes or other skin problems
  • Diarrhea
  • Fatigue
  • Nausea
  • Swelling (edema)

More serious side effects can occur, such as heart problems, eye problems, or lung inflammation. Patients should report any unusual symptoms to their healthcare provider promptly.[5]

It’s important to note that the side effects and their frequency can vary depending on the specific condition being treated and other factors. Your healthcare team will monitor you closely while you’re taking trametinib and can provide more personalized information about potential side effects.

Aspect Details
Drug Name Trametinib (also known as GSK1120212, Mekinist)
Drug Class MEK inhibitor
Administration Oral, typically 2 mg once daily
Cancer Types Studied Solid tumors, leukemias, thyroid cancer, lung cancer, multiple myeloma
Key Outcomes Measured Tumor response rate, progression-free survival, overall survival, safety profile
Common Side Effects Skin rashes, diarrhea, fatigue, blood pressure changes
Potential Benefits May shrink tumors or slow cancer growth in some patients with advanced cancers
Ongoing Research Optimal dosing, combination therapies, identifying responsive patient populations

FAQ

  • What is trametinib? Trametinib is a MEK inhibitor, which means it blocks proteins called MEK1 and MEK2 that are involved in cancer cell growth. It is being studied as a potential treatment for various types of cancer.
  • What types of cancer is trametinib being studied for? Trametinib is being investigated for several cancer types, including solid tumors, leukemias, thyroid cancer, lung cancer, and multiple myeloma. It is often studied in patients with advanced or refractory cancers that have not responded well to other treatments.
  • How is trametinib administered in clinical trials? In most clinical trials, trametinib is given orally (by mouth) once daily. The typical dose is 2 mg per day, but some trials may use different doses or combine it with other drugs.
  • What are some potential side effects of trametinib? Common side effects of trametinib can include skin rashes, diarrhea, fatigue, and changes in blood pressure. More serious side effects may include eye problems, heart issues, and liver dysfunction. Clinical trials closely monitor patients for any adverse events.
  • How do researchers measure if trametinib is working in clinical trials? Researchers assess the effectiveness of trametinib using various measures, including tumor response rate, progression-free survival, overall survival, and changes in specific biomarkers. They also evaluate the drug's safety profile and how well patients tolerate the treatment.

Ongoing Clinical Trials on Trametinib

  • Study on the Effectiveness of Sirolimus and Trametinib for Treating Diffuse Intrinsic Pontine Glioma in Children Aged 3-18 Years

    Recruiting

    1 1 1
    Investigated drugs:
    Poland

  • Study on Dabrafenib, Trametinib, and Imatinib for Patients with Rare and Hard-to-Treat Cancers

    Recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Denmark France Germany Hungary The Netherlands +1

  • Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study on the Effectiveness of Pembrolizumab and Ipilimumab in Melanoma Patients with Brain Metastases Requiring Steroid Treatment

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark

  • Study of Drug Combination Treatment Based on Tumor Molecular Changes in Patients with Advanced or Metastatic Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Drug Combination for Advanced Cancer Patients with Known Molecular Profile – FINPROVE Study

    Recruiting

    1 1 1
    Investigated drugs:
    Finland

  • Study Comparing Trametinib and Vinblastine for Children and Young Adults with Newly Diagnosed Low-Grade Glioma with Wild-Type BRAF Gene

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety and Effects of CC-92480 with Dexamethasone and Drug Combinations for Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    1 1 1
    Investigated drugs:
    Norway Spain

Glossary

  • MEK inhibitor: A type of drug that blocks proteins called MEK1 and MEK2, which are involved in cancer cell growth and survival.
  • Refractory cancer: Cancer that does not respond to treatment or has stopped responding to treatment.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent increasing the dose or require a dose reduction.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without their cancer getting worse.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • Biomarker: A biological molecule found in blood, other body fluids, or tissues that can be used to measure disease progress or the effects of treatment.
  • BRAF mutation: A specific change in the BRAF gene that can contribute to cancer growth and is found in some types of cancer.

References

  1. https://clinicaltrials.gov/study/NCT06262919
  2. https://clinicaltrials.gov/study/NCT04619316
  3. https://clinicaltrials.gov/study/NCT01958112
  4. https://clinicaltrials.gov/study/NCT01553851
  5. https://clinicaltrials.gov/study/NCT02070549
  6. https://clinicaltrials.gov/study/NCT02140840
  7. https://clinicaltrials.gov/study/NCT03232892
  8. https://clinicaltrials.gov/study/NCT06582745